Founded in 2023, Allink Biotherapeutics pioneers precision medicine through breakthrough bispecific antibodies and ADC therapeutics that transcend conventional treatment limitations. Our interdisciplinary teams unite rigorous scientific methodology with unwavering patient-centered purpose.
Our Foundation
Proprietary Technology Platforms
Strategically Diversified Pipeline
Clinical-Stage Assets Advancing Patient Care
We have established next-gen technology platforms that bridge scientific discovery and meaningful therapeutic interventions. Our two ADC programs have advanced to global Phase I clinical trials - demonstrating how collaborative innovation translates directly into clinical value. Multiple early-stage programs have achieved pipeline candidacy, creating a robust foundation for accelerated development and sustained global impact.
Allink was established in 2023
Over 5 patents covering products and technology
Nearly 30 years of experience in biopharmaceutical and ADC R&D
More than 10 innovative pipelines
Expert R&D Team
Interdisciplinary team with experience in the development of modalities and stage
Efficient Execution
The team successfully delivered 20+ IND applications and secured 3 BLA approvals
Proprietary Platform
Proprietary platform for bispecific antibody and bi-epitope antibody screening
International Collaboration
Fully leverage international collaboration opportunities to accelerate the product development
